FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan

Rhea-AI Summary

Today at 5pm ET marks the final deadline for ovarian cancer victims to vote on Johnson & Johnson's (NYSE: JNJ) $8 billion talcum powder settlement. The plan, with a net present value of $6.475 billion, aims to compensate current and future claimants harmed by J&J's talc products. Ovarian cancer claimants are expected to receive $75,000 to $150,000 each on average.

The Ad Hoc Group of Counsel, representing over 77,500 individuals, urges all affected to vote YES, emphasizing that 75% approval is needed. They refute claims by opposing law firms, stating that the settlement offers a fair and timely resolution compared to prolonged litigation. Claimants can vote at www.OfficialTalcClaims.com or by calling 1-888-431-4056.

Positive

• J&J offering approximately $8 billion settlement for talcum powder claims
• Ovarian cancer claimants expected to receive $75,000 to $150,000 each on average
• Settlement aims to compensate both current and future claimants

Negative

• Potential legal liability for J&J related to talcum powder products
• Risk of settlement not being approved if 75% approval threshold is not met
• Possibility of continued litigation and associated costs if settlement fails

Legal Expert

This news is highly significant for Johnson & Johnson and the thousands of claimants involved in the talcum powder litigation. The approximately $8 billion settlement plan, with a net present value of $6.475 billion, represents a major financial and legal milestone for J&J.

Several key points stand out:

• The settlement aims to compensate both current and future claimants, with ovarian cancer victims expected to receive between $75,000 and $150,000 on average.
• The voting process requires a 75% approval rate from claimants, highlighting the importance of participation.
• The Ad Hoc Group of Counsel, representing over 77,500 individuals, strongly supports the settlement, citing the lengthy litigation process and low success rate in individual trials.
• Opposing law firms' arguments against the settlement are addressed, revealing potential conflicts of interest related to legal fees.

From a legal perspective, this settlement could set a precedent for how large corporations handle mass tort liabilities. The inclusion of future claimants in the settlement structure is particularly noteworthy, as it addresses long-term liability concerns. However, the use of bankruptcy as a resolution mechanism for mass torts remains controversial and could face scrutiny in future cases.

The tight deadline and last-minute push for 'yes' votes suggest a critical juncture in the settlement process. If approved, this could mark a significant shift in how such large-scale product liability cases are resolved, potentially influencing future corporate strategies and legal approaches in similar situations.

Financial Analyst

The impending deadline for J&J's talc settlement vote carries substantial financial implications. The $8 billion settlement, with a net present value of $6.475 billion, represents a significant financial commitment for Johnson & Johnson, one of the largest consumer health companies globally.

Key financial considerations include:

• The settlement's impact on J&J's balance sheet and future cash flows
• Potential effects on investor confidence and stock performance
• Long-term financial benefits of resolving this lingering liability

While the settlement amount is substantial, it provides financial clarity and caps J&J's liability exposure. This could be viewed positively by investors, as it removes a major source of uncertainty. However, the immediate financial impact may be tempered by J&J's strong balance sheet and diverse revenue streams.

It's worth noting that J&J's stock performance has remained relatively stable despite this ongoing litigation, suggesting that the market has largely priced in the expected settlement costs. The resolution of this issue could allow management to refocus on core business strategies and growth initiatives, potentially driving long-term shareholder value.

Investors should monitor the voting outcome closely, as it will significantly influence J&J's financial outlook and legal risk profile going forward. A successful settlement could pave the way for improved market sentiment and potentially lead to a re-rating of the stock.

Medical Research Analyst

The J&J talc settlement brings to light critical issues at the intersection of consumer products and public health. From a medical research perspective, several points warrant attention:

• The link between talcum powder use and ovarian cancer remains a subject of ongoing scientific debate.
• Long-term health effects of talc exposure highlight the need for rigorous safety testing of consumer products.
• The settlement's provision for future claimants acknowledges the potential for delayed onset of related health issues.

This case underscores the importance of post-market surveillance and long-term safety studies for widely used consumer products. The scientific community continues to investigate the potential carcinogenic effects of talc, with some studies suggesting a modest increase in ovarian cancer risk associated with perineal talc use.

The settlement's structure, accommodating both current and future claimants, reflects an understanding of the complex nature of cancer development and the potential for long latency periods between exposure and disease onset. This approach could set a precedent for how other product liability cases involving long-term health effects are handled.

Moving forward, this case may spur increased funding and focus on research into the safety of common household products and their long-term health impacts. It also highlights the need for clear communication of potential risks to consumers, even when scientific consensus is not fully established.

For the medical community, this settlement emphasizes the importance of thorough patient history-taking, including exposure to common household products, when assessing cancer risk factors.

Those Who Previously Voted “No” Can Still Switch Their Vote to “Yes”

NEW YORK--(BUSINESS WIRE)-- Today at 5pm ET is the final deadline for tens of thousands of ovarian cancer victims or their representatives to vote on the approximately $8 billion Johnson & Johnson (“J&J”) (NYSE: JNJ) talcum powder settlement, leaving claimants just hours to act.

Haven't voted in favor of the talcum powder plan yet? There's still time. (Graphic: Business Wire)

Talc claimants can vote on the plan at www.OfficialTalcClaims.com or by calling 1-888-431-4056.

The approximately $8 billion plan, which has a net present value of $6.475 billion, will compensate current and future claimants who were harmed by J&J’s talcum powder products, putting an end to a lengthy, frustrating litigation process. Under the plan, ovarian cancer claimants are expected to receive an average of $75,000 to $150,000 each.

In order for claimants and families to achieve the timely and fair compensation they deserve, at least 75% of the people casting votes must vote YES on the plan.

The Ad Hoc Group of Counsel – representing more than 77,500 individuals in this matter – urges all individuals harmed by J&J baby powder products and their attorneys to take action now before the deadline of 5pm ET today.

If you have already voted “no” and are having second thoughts, it’s not too late: Only your latest vote counts and will override any prior vote you cast. Please know that your voting decision is completely confidential.

The Ad Hoc Group of Counsel believes that law firms opposing the settlement have attempted to sway voters towards continued litigation, because doing so would result in hundreds of millions of dollars in fees to the lawyers. Those extra payments to attorneys would not be available through a bankruptcy settlement.

At this critical time, the Ad Hoc Group of Counsel is providing detailed responses to the misleading claims put forth by opposing law firms so that all J&J claimants can make an informed voting decision.

• What They Claim: There is no way of knowing how much claimants will be paid or when.
  The Truth: Under the J&J bankruptcy plan, ovarian cancer claimants are projected to receive an average recovery of between $75,000 and $150,000.

• What They Claim: Claimants are being deprived of the right to choose to settle.
  The Truth: By voting on J&J’s bankruptcy plan, people are actually making their voice heard and preserving their ability to participate in this historic settlement of approximately $8 billion through a process that eliminates litigation risk.

• What They Claim: Claimants have a better chance of succeeding if they vote “no” and take their case to trial.
  The Truth: In over a decade of litigation, just 17 ovarian cancer cases have gone to trial. J&J and its subsidiaries have prevailed in 16 of those cases, with plaintiffs recovering no money.

• What They Claim: Resolution through multidistrict litigation (MDL) is the fairest way to handle these cases.
  The Truth: The law firms opposing the settlement have had ample time to reach a resolution through MDL, but their efforts to reach a consensus have not been successful.

• What They Claim: There are thousands of “fantasy cases” among those voting to support the plan.
  The Truth: Our clients are real people who have suffered greatly as a result of using J&J talc products. This statement is deeply offensive to the tens of thousands of talc victims represented by the Ad Hoc Group of Counsel.

• What They Claim: People diagnosed with ovarian cancer in the future due to their past use of talc products won't be able to hold J&J accountable.
  The Truth: A future claims representative is representing the rights of future claimants, and those future victims will have the same recovery rights as current claimants.

• What They Claim: Voting against the plan will make J&J suffer.
  The Truth: Voting “no” hurts victims, not J&J. If the proposed plan fails to garner enough “yes” votes, these victims will not receive compensation for their suffering for years, if ever.

• What They Claim: If J&J is able to resolve this matter through bankruptcy, other corporations will also seek to escape mass tort liability and jury trials through the bankruptcy process.
  The Truth: If this vote succeeds, J&J will be paying an historic amount - approximately $8 billion - to settle claims. The company is being held accountable for the harm its products caused.

Ovarian cancer survivor Tamika Evans, 47, of Chicago voted to approve the plan. She stated: “I support this settlement because I need help with my ongoing treatment costs and to recover from the medical debt. It’s about more than money – it’s about acknowledging the impact on our lives.”

As Anna Maria Sanderford, 61, of Arizona, stated: “We need to get this settlement done so we can go on with our lives and do what we want with the time we have left.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20240726806059/en/

Docket Communications

talc@docketcommunications.com

Source: Ad Hoc Group of Counsel

FAQ

What is the deadline for voting on the J&J talc settlement?

The final deadline for voting on the Johnson & Johnson (JNJ) talc settlement is 5pm ET today.

How much is J&J offering in the talcum powder settlement?

Johnson & Johnson (JNJ) is offering approximately $8 billion in the talcum powder settlement, with a net present value of $6.475 billion.

How much compensation can ovarian cancer claimants expect from the JNJ talc settlement?

Ovarian cancer claimants are expected to receive an average of $75,000 to $150,000 each from the Johnson & Johnson (JNJ) talc settlement.

What percentage of votes is needed to approve the J&J talc settlement?

At least 75% of the people casting votes must vote YES on the Johnson & Johnson (JNJ) talc settlement plan for it to be approved.